SCHEMBL22492652

SCHEMBL22492652

CC(NS(=O)(=O)c1ccc([N+](=O)[O-])cc1)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.68
MMP9 P14780 5/20 0.68
MMP1 P03956 4/20 0.68
MMP13 P45452 4/20 0.68
MMP3 P08254 2/20 0.68
MMP7 P09237 2/20 0.68
SLC1A3 P43003 1/20 0.63
SLC1A2 P43004 1/20 0.63
SLC1A1 P43005 1/20 0.63
ADAMTS4 O75173 1/20 0.63
CA2 P00918 5/20 0.57
CA12 O43570 4/20 0.57
CA9 Q16790 4/20 0.57
CA14 Q9ULX7 3/20 0.57
CA1 P00915 3/20 0.56
MMP8 P22894 2/20 0.56
CA3 P07451 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56
CA5A P35218 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5193258 1.00 MMP2 (0.68) MMP2MMP9MMP1MMP13MMP3
P-Nitrophenol SCHEMBL7776372 0.89 MMP9 (0.57) MMP2MMP9MMP1MMP13MMP3
SCHEMBL6422526 0.85 MMP2 (0.92) MMP2MMP9MMP1MMP13MMP3
SCHEMBL6422533 0.85 MMP2 (0.92) MMP2MMP9MMP1MMP13MMP3
SCHEMBL26616333 0.85 MMP2 (0.92) MMP2MMP9MMP1MMP13MMP3
SCHEMBL8575008 0.82 CA2 (0.65) MMP2MMP9MMP1MMP13MMP3
SCHEMBL4428929 0.81 MMP2 (1.00) MMP2MMP9MMP1MMP13MMP3
SCHEMBL5190668 0.81 MMP2 (0.64) MMP2MMP9MMP1MMP13MMP3
SCHEMBL4428937 0.81 MMP2 (1.00) MMP2MMP9MMP1MMP13MMP3
SCHEMBL3599190 0.81 MMP2 (1.00) MMP2MMP9MMP1MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3846803-A2 MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2021-07-14 EP disclosed
EP-3717453-A2 CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF Ultragenyx Pharmaceutical Inc. (US) 2020-10-07 EP disclosed